Latest / Decera Clinical Education Oncology Podcast
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:
How the experts currently use CDK4/6 inhibitors in clinical practice
Clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021
Strategies for counseling patients receiving CDK4/6 inhibitors
Presenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.